2 weeks Ago By ABMN Staff
Cerity Partners LLC trimmed its holdings in shares of Cytokinetics, Incorporated ( NASDAQ:CYTK – Free Report ) by 21.0% in the 4th quarter, Holdings Channel.com reports.
The firm owned 4,066 shares of the biopharmaceutical company’s stock after selling 1,080 shares during the period. Cerity Partners LLC’s holdings in Cytokinetics were worth $209,000 as of its most recent SEC filing. A number of other hedge funds have also recently made changes to their positions in the stock.
Harvey Capital Management Inc. purchased a new position in Cytokinetics during the fourth quarter valued at $1,040,000. abrdn plc increased its stake in Cytokinetics by 29.
4% during the 4th quarter. abrdn plc now owns 450,513 shares of the biopharmaceutical company’s stock valued at $21,192,000 after purchasing an additional 102,457 shares in the last quarter. AlphaQuest LLC raised its holdings in Cytokinetics by 113,500.
0% in the fourth quarter. AlphaQuest LLC now owns 1,136 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 1,135 shares during the last quarter. Vanguard Group Inc.
raised its holdings in Cytokinetics by 1.3% in the fourth quarter. Vanguard Group Inc.
now owns 11,915,821 shares of the biopharmaceutical company’s stock worth $560,520,000 after buying an additional 154,216 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Cytokinetics by 1.
0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,335,189 shares of the biopharmaceutical company’s stock worth $62,807,000 after buying an additional 13,798 shares in the last quarter.
Wall Street Analysts Forecast Growth A number of equities analysts recently weighed in on the stock. Bank of America decreased their price objective on shares of Cytokinetics from $62.00 to $54.
00 and set a “neutral” rating for the company in a report on Tuesday, April 15th. Stifel Nicolaus initiated coverage on Cytokinetics in a research note on Wednesday, January 22nd. They issued a “buy” rating and a $80.
00 price target for the company. Citigroup began coverage on Cytokinetics in a research report on Friday, February 7th. They set a “buy” rating and a $86.
00 price objective on the stock. JMP Securities reissued a “market outperform” rating and issued a $78.00 target price on shares of Cytokinetics in a research report on Thursday, April 10th.
Finally, Evercore ISI upgraded shares of Cytokinetics to a “strong-buy” rating in a research note on Friday, February 7th. Two analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $79.
13. Cytokinetics Price Performance NASDAQ CYTK opened at $40.33 on Friday.
The stock has a market cap of $4.81 billion, a price-to-earnings ratio of -7.50 and a beta of 0.
94. Cytokinetics, Incorporated has a 12 month low of $32.74 and a 12 month high of $68.
44. The company’s 50 day moving average is $42.19 and its two-hundred day moving average is $47.
29. The company has a current ratio of 9.28, a quick ratio of 9.
28 and a debt-to-equity ratio of 5.93. Cytokinetics ( NASDAQ:CYTK – Get Free Report ) last released its earnings results on Thursday, February 27th.
The biopharmaceutical company reported ($1.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.
03. The firm had revenue of $16.93 million for the quarter, compared to analysts’ expectations of $14.
26 million. As a group, research analysts anticipate that Cytokinetics, Incorporated will post -5.24 earnings per share for the current year.
Insider Transactions at Cytokinetics In related news, EVP Fady Ibraham Malik sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $45.98, for a total value of $91,960.
00. Following the transaction, the executive vice president now directly owns 116,071 shares of the company’s stock, valued at approximately $5,336,944.58.
The trade was a 1.69 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link .
Also, Director Wendall Wierenga sold 20,000 shares of the stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $38.46, for a total transaction of $769,200.
00. Following the sale, the director now directly owns 24,848 shares of the company’s stock, valued at approximately $955,654.08.
This trade represents a 44.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here .
Insiders sold a total of 88,360 shares of company stock valued at $3,643,645 over the last 90 days. Company insiders own 3.40% of the company’s stock.
Cytokinetics Profile ( Free Report ) Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Read More Want to see what other hedge funds are holding CYTK? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Cytokinetics, Incorporated ( NASDAQ:CYTK – Free Report ). Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter .
.
